Helixgate

Helixgate

Uncategorized

Team approach to lowering high blood pressure worked even in ‘a tough landscape’

It’s the leading risk factor for the leading cause of death in the United States and around the world: high blood pressure, the prime mover in heart attacks and strokes.

High blood pressure is treatable, but despite having access to effective and affordable medications, more than half of Americans still have uncontrolled hypertension, with rates going up in sync with adverse social determinants of health. 

Read the rest…

Read More

Published

on

It’s the leading risk factor for the leading cause of death in the United States and around the world: high blood pressure, the prime mover in heart attacks and strokes.

High blood pressure is treatable, but despite having access to effective and affordable medications, more than half of Americans still have uncontrolled hypertension, with rates going up in sync with adverse social determinants of health. 

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage

From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage

Published

on

In nuclear medicine, innovation alone isn’t enough. What matters is whether it can be delivered on time, every time, because timing is critical for our patients. And that delivery promise must hold up under real-world pressure – from routine variability to sudden disruptions that can reroute global logistics overnight.​ ​Read More

Continue Reading

Uncategorized

KRAS drugmakers take another, better swing at lung cancer

Published

on

SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.

KRAS mutations drive around a quarter of all cancer cases and …

Continue Reading

Uncategorized

UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition

Published

on

UCB plans to pay $650 million to Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio.

The deal comes with as much as $500 million in milestone payments.

Neurona is developing a treatment …

Continue Reading
Advertisement

Trending